prikaz prve stranice dokumenta Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
  Preuzmi
PDF 1.02 MB
Znanstveni rad - Izvorni znanstveni rad
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
BMC Proceedings, 18 (2024), Suppl 3; 2. https://doi.org/10.1186/s12919-023-00287-6
Hochmair, Maximilian J.; Unk, Mojca; Spasic, Jelena; Cerić, Timur; Konsoulova, Assia; Dediu, Mircea; Bogos, Krisztina; Hegmane, Alinta; Oselin, Kersti; Stojiljkovic, Marko; Roblek, Tina; Jakopović, Marko

Citiranost:
,
Citirajte ovaj rad

Hochmair, M. J., Unk, M., Spasic, J., Cerić, T., Konsoulova, A., Dediu, M. ... Jakopović, M. (2024). Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proceedings, 18. (Suppl 3). doi: 10.1186/s12919-023-00287-6

Hochmair, Maximilian J., et al. "Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability." BMC Proceedings, vol. 18, br. Suppl 3, 2024. https://doi.org/10.1186/s12919-023-00287-6

Hochmair, Maximilian J., Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, et al. "Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability." BMC Proceedings 18, br. Suppl 3 (2024). https://doi.org/10.1186/s12919-023-00287-6

Hochmair, M. J., et al. (2024) 'Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability', BMC Proceedings, 18(Suppl 3). doi: 10.1186/s12919-023-00287-6

Hochmair MJ, Unk M, Spasic J, Cerić T, Konsoulova A, Dediu M, i sur.. Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proceedings [Internet]. 18.01.2024. [pristupljeno 01.04.2025.];18(Suppl 3). doi: 10.1186/s12919-023-00287-6

M. J. Hochmair, et al., "Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability", BMC Proceedings, vol. 18, br. Suppl 3, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:072153. [Citirano: 01.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:072153
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
AutorMaximilian J. Hochmair
AutorMojca Unk
AutorJelena Spasic
AutorTimur Cerić
AutorAssia Konsoulova
AutorMircea Dediu
AutorKrisztina Bogos
AutorAlinta Hegmane
AutorKersti Oselin
AutorMarko Stojiljkovic
AutorTina Roblek
AutorMarko Jakopović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3-2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as "typical" EGFR alterations. Recent advancements in... Više understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations.This article presents the outcomes of a Virtual Meeting conducted on the online platform (provided Within3©) from September 19 to October 30, 2022. The meeting focused on addressing the challenges in the diagnosis and treatment of NSCLC patients with EGFR exon 20 insertion mutations. The participants consisted of healthcare professionals from ten Central and Eastern European countries who shared their experiences and opinions on various aspects, including epidemiology, treatment options, and diagnostic approaches employed in their respective healthcare institutions. The discussions were facilitated through open-ended and multiple-choice questions.The primary objective of this article is to provide an overview of the identified challenges associated with the diagnosis and treatment of this heterogeneous disease, based on the assessments of the meeting participants. Among the major emerging challenges discussed, the reimbursement issues concerning next-generation sequencing (NGS), a recommended method in NSCLC molecular diagnosis, and the availability of approved targeted treatments to enhance patient outcomes were of paramount importance. Furthermore, fostering community awareness of lung cancer and promoting harmonized lung cancer care were identified as areas deserving greater attention. Notably, the rapidly evolving treatment landscape, particularly with NGS for NSCLC patients with genomic alterations like EGFR, ALK, RET, MET, NTRK, and ROS1, necessitates prioritizing the development of new drugs, even for the relatively smaller subgroup with exon 20 insertion mutations. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBMC Proceedings
Brojčani podacivol. 18, br. Suppl 3, 2
e-ISSN1753-6561
DOIhttps://doi.org/10.1186/s12919-023-00287-6
URN:NBNurn:nbn:hr:105:072153
Datum objave publikacije2024-01-18
URL dokumentahttps://bmcproc.biomedcentral.com/articles/10.1186/s12919-023-00287-6
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-12-11 13:31:30
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.